Research ArticleOriginal Article
Open Access

Identification of cystic fibrosis transmembrane conductance regulator gene (CFTR) variants

A retrospective study on the western and southern regions of Saudi Arabia

Talal Almaghamsi, Wejdan Ba Attiyah, Mona Bahasan, Badi A. Alotaibi, Shahad F. AlAhmadi, Mehenaz Hanbazazh, Abeer Zakariyah, Rimah A. Saleem, Munaifah K. AlAnezi and Yousef Hawsawi
Saudi Medical Journal October 2023, 44 (10) 987-994; DOI: https://doi.org/10.15537/smj.2023.44.10.20230290

References

  1. 1.↵
    1. Turcios NL.
    Cystic fibrosis lung disease: An overview. Respir Care 2020;65: 233–251.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Stoltz DA,
    2. Meyerholz DK,
    3. Welsh MJ.
    Origins of cystic fibrosis lung disease. N Engl J Med 2015; 372 : 1574–1575.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Mall MA,
    2. Hartl D.
    CFTR: cystic fibrosis and beyond. Eur Respir J 2014; 44: 1042–1054.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Rubin BK.
    Cystic fibrosis: myths, mistakes, and dogma. Paediatr Respir Rev 2014; 15: 113–116.
    OpenUrl
  5. 5.↵
    1. Wielputz MO,
    2. Eichinger M,
    3. Biederer J,
    4. Wege S,
    5. Stahl M,
    6. Sommerburg O, et al.
    Imaging of cystic fibrosis lung disease and clinical interpretation. Rofo 2016; 188: 834–845.
    OpenUrl
  6. 6.↵
    1. Woods JC,
    2. Wild JM,
    3. Wielputz MO,
    4. Clancy JP,
    5. Hatabu H,
    6. Kauczor HU, et al.
    Current state of the art MRI for the longitudinal assessment of cystic fibrosis. J Magn Reson Imaging 2020; 52: 1306–1320.
    OpenUrl
  7. 7.↵
    1. Lopes-Pacheco M.
    CFTR modulators: The changing face of cystic fibrosis in the era of precision medicine. Front Pharmacol 2019;10:1662.
    OpenUrlCrossRef
  8. 8.↵
    1. Chen Q,
    2. Shen Y,
    3. Zheng J.
    A review of cystic fibrosis: Basic and clinical aspects. Animal Model Exp Med 2021; 4: 220–232.
    OpenUrl
  9. 9.↵
    1. Moskowitz SM,
    2. Chmiel JF,
    3. Sternen DL,
    4. Cheng E,
    5. Gibson RL,
    6. Marshall SG, et al.
    Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders. Genet Med 2008; 10: 851–868.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Antunovic SS,
    2. Lukac M,
    3. Vujovic D.
    Longitudinal cystic fibrosis care. Clin Pharmacol Ther 2013; 93: 86–97.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Nazer H,
    2. Riff E,
    3. Sakati N,
    4. Mathew R,
    5. Majeed-Saidan MA,
    6. Harfi H.
    Cystic fibrosis in Saudi Arabia. Eur J Pediatr 1989; 148: 330–332.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Banjar H,
    2. Angyalosi G.
    The road for survival improvement of cystic fibrosis patients in Arab countries. Int J Pediatr Adolesc Med 2015; 2: 47–58.
    OpenUrl
  13. 13.↵
    1. Habib AR,
    2. Kajbafzadeh M,
    3. Desai S,
    4. Yang CL,
    5. Skolnik K,
    6. Quon BS.
    A systematic review of the clinical efficacy and safety of CFTR modulators in cystic fibrosis. Sci Rep 2019; 9: 7234.
    OpenUrl
  14. 14.↵
    1. Estivill X,
    2. Bancells C,
    3. Ramos C.
    Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations. The biomed CF mutation analysis consortium. Hum Mutat 1997; 10: 135–154.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Banjar HH,
    2. Tuleimat L,
    3. El Seoudi AAA,
    4. Mogarri I,
    5. Alhaider S,
    6. Nizami IY, et al.
    Genotype patterns for mutations of the cystic fibrosis transmembrane conductance regulator gene: a retrospective descriptive study from Saudi Arabia. Ann Saudi Med 2020; 40: 15–24.
    OpenUrl
  16. 16.
    1. Kerem B,
    2. Rommens JM,
    3. Buchanan JA,
    4. Markiewicz D,
    5. Cox TK,
    6. Chakravarti A, et al.
    Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245 :1073–1080.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Banjar H,
    2. Al-Mogarri I,
    3. Nizami I,
    4. Al-Haider S,
    5. AlMaghamsi T,
    6. Alkaf S, et al.
    Geographic distribution of cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in Saudi Arabia. Int J Pediatr Adolesc Med 2021; 8: 25–28.
    OpenUrl
  18. 18.
    1. el-Harith EA,
    2. Dörk T,
    3. Stuhrmann M,
    4. Abu-Srair H,
    5. al-Shahri A,
    6. Keller KM, et al.
    Novel and characteristic CFTR mutations in Saudi Arab children with severe cystic fibrosis. J Med Genet 1997; 34: 996–999.
  19. 19.
    1. Zielenski J,
    2. Bozon D,
    3. Kerem B,
    4. Markiewicz D,
    5. Durie P,
    6. Rommens JM, et al.
    Identification of mutations in exons 1 through 8 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics 1991; 10: 229–235.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.
    1. Dörk T,
    2. El-Harith EH,
    3. Stuhrmann M,
    4. Macek M, Jr.,
    5. Egan M,
    6. Cutting GR, et al.
    Evidence for a common ethnic origin of cystic fibrosis mutation 3120+1G-->A in diverse populations. Am J Hum Genet 1998; 63: 656–62.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.
    1. Wilschanski M,
    2. Zielenski J,
    3. Markiewicz D,
    4. Tsui LC,
    5. Corey M,
    6. Levison H, et al.
    Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations. J Pediatr 1995; 127: 705–710.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.
    1. Clavel C,
    2. Pennaforte F,
    3. Pigeon F,
    4. Verlingue C,
    5. Birembaut P,
    6. Férec C.
    Identification of four novel mutations in the cystic fibrosis transmembrane conductance regulator gene: E664X, 2113delA, 306delTAGA, and delta M1140. Hum Mutat 1997; 9: 368–369.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Lucarelli M,
    2. Bruno SM,
    3. Pierandrei S,
    4. Ferraguti G,
    5. Stamato A,
    6. Narzi F, et al.
    A Genotypic-oriented view of CFTR genetics highlights specific mutational patterns underlying clinical macrocategories of cystic fibrosis. Mol Med 2015; 21: 257–275.
    OpenUrlCrossRefPubMed
  24. 24.
    1. Molinski SV,
    2. Gonska T,
    3. Huan LJ,
    4. Baskin B,
    5. Janahi IA,
    6. Ray PN, et al.
    Genetic, cell biological, and clinical interrogation of the CFTR mutation c.3700 A>G (p.Ile1234Val) informs strategies for future medical intervention. Genet Med 2014; 16: 625–632.
    OpenUrlCrossRefPubMed
  25. 25.
    1. Schrijver I,
    2. Ramalingam S,
    3. Sankaran R,
    4. Swanson S,
    5. Dunlop CL,
    6. Keiles S, et al.
    Diagnostic testing by CFTR gene mutation analysis in a large group of Hispanics: novel mutations and assessment of a population-specific mutation spectrum. J Mol Diagn 2005; 7: 289–299.
    OpenUrlPubMedWeb of Science
  26. 26.
    1. Rohlfs EM,
    2. Zhou Z,
    3. Sugarman EA,
    4. Heim RA,
    5. Pace RG,
    6. Knowles MR, et al.
    The I148T CFTR allele occurs on multiple haplotypes: a complex allele is associated with cystic fibrosis. Genet Med 2002; 4: 319–323.
    OpenUrlPubMedWeb of Science
  27. 27.
    1. Schwartz KM,
    2. Pike-Buchanan LL,
    3. Muralidharan K,
    4. Redman JB,
    5. Wilson JA,
    6. Jarvis M, et al.
    Identification of cystic fibrosis variants by polymerase chain reaction/oligonucleotide ligation assay. J Mol Diagn 2009; 11: 211–215.
    OpenUrlCrossRefPubMed
  28. 28.
    1. Alibakhshi R,
    2. Kianishirazi R,
    3. Cassiman JJ,
    4. Zamani M,
    5. Cuppens H.
    Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. J Cyst Fibros 2008; 7: 102–109.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.
    1. Bergougnoux A,
    2. Viart V,
    3. Miro J,
    4. Bommart S,
    5. Molinari N,
    6. des Georges M, et al.
    Should diffuse bronchiectasis still be considered a CFTR-related disorder? J Cyst Fibros 2015; 14: 646–653.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Nemat Farahzadi H,
    2. Akbari MT.
    Analysis variants of the CFTR gene in iranian cystic fibrosis patients. J Human Gen Genom 2020; 4: e123474.
    OpenUrl
  31. 31.
    1. Sharma N,
    2. Singh M,
    3. Kaur G,
    4. Thapa BR,
    5. Prasad R.
    Identification and characterization of CFTR gene mutations in Indian CF patients. Ann Hum Genet 2009; 73: 26–33.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Castaldo G,
    2. Polizzi A,
    3. Tomaiuolo R,
    4. Cazeneuve C,
    5. Girodon E,
    6. Santostasi T, et al.
    Comprehensive cystic fibrosis mutation epidemiology and haplotype characterization in a southern Italian population. Ann Hum Genet 2005; 69: 15–24.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.
    1. Steiner B,
    2. Rosendahl J,
    3. Witt H,
    4. Teich N,
    5. Keim V,
    6. Schulz HU, et al.
    Common CFTR haplotypes and susceptibility to chronic pancreatitis and congenital bilateral absence of the vas deferens. Hum Mutat 2011;32: 912–920.
    OpenUrlCrossRefPubMed
  34. 34.
    1. Sobush KT,
    2. Thornburg CD,
    3. Voynow JA,
    4. Davis SD,
    5. Peterson-Carmichael SL.
    A 2-year-old girl with co-inherited cystic fibrosis and sickle cell-β+ thalassemia presenting with recurrent vaso-occlusive events during cystic fibrosis pulmonary exacerbations: a case report. J Med Case Rep 2013; 7: 203.
    OpenUrl
  35. 35.
    1. Gaikwad A,
    2. Khan S,
    3. Kadam S,
    4. Kadam K,
    5. Dighe V,
    6. Shah R, et al.
    The CFTR gene mild variants poly-T, TG repeats and M470V detection in Indian men with congenital bilateral absence of vas deferens. Andrologia 2018; 50.
  36. 36.
    1. Minarowski L,
    2. Minarowska A,
    3. Sands D,
    4. Kowalczuk O,
    5. Chyczewski L,
    6. Chyczewska E, et al.
    Single nucleotide polymorphims 1540G/A, 2694T/G and 4521G/A of <em>CFTR</em> gene and their association with cystic fibrosis phenotype. Eur Respir J 2014; 44: P1201.
    OpenUrl
  37. 37.
    1. Atag E,
    2. Bas Ikizoglu N,
    3. Ergenekon AP,
    4. Gokdemir Y,
    5. Eralp EE,
    6. Ata P, et al.
    Novel mutations and deletions in cystic fibrosis in a tertiary cystic fibrosis center in Istanbul. Pediatr Pulmonol 2019; 54: 743–750.
    OpenUrlCrossRef
  38. 38.↵
    1. Farhat R,
    2. Puissesseau G,
    3. El-Seedy A,
    4. Pasquet MC,
    5. Adolphe C,
    6. Corbani S, et al.
    N1303K (c.3909C>G) mutation and splicing: implication of its c.[744-33GATT(6); 869+11C>T] complex allele in CFTR exon 7 aberrant splicing. Biomed Res Int 2015; 2015: 138103.
    OpenUrl
  39. 39.
    1. Grangeia A,
    2. Alves S,
    3. Gonçalves L,
    4. Gregório I,
    5. Santos AC,
    6. Barros H, et al.
    Spectrum of CFTR gene sequence variants in a northern Portugal population. Pulmonology 2018; 24: 3–9.
    OpenUrl
  40. 40.↵
    1. Ivanov M,
    2. Matsvay A,
    3. Glazova O,
    4. Krasovskiy S,
    5. Usacheva M,
    6. Amelina E, et al.
    Targeted sequencing reveals complex, phenotype-correlated genotypes in cystic fibrosis. BMC Medical Genomics 2018; 11: 13.
    OpenUrl
  41. 41.↵
    1. Harness-Brumley CL,
    2. Elliott AC,
    3. Rosenbluth DB,
    4. Rghavan D,
    5. Jain R.
    Gender differences in outcomes of patients with cystic fibrosis. J Womens Health (Larchmt) 2014; 23: 1012–1020.
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Demko CA,
    2. Byard PJ,
    3. Davis PB.
    Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol 1995; 48: 1041–1049.
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    1. Banjar H,
    2. Kambouris M,
    3. Meyer BF,
    4. al-Mehaidib A,
    5. Mogarri I.
    Geographic distribution of cystic fibrosis transmembrane regulator gene mutations in Saudi Arabia. Ann Trop Paediatr 1999;19: 69–73.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. El Mouzan MI,
    2. Al Salloum AA,
    3. Al Herbish AS,
    4. Qurachi MM,
    5. Al Omar AA.
    Consanguinity and major genetic disorders in Saudi children: a community-based cross-sectional study. Ann Saudi Med 2008; 28: 169–173.
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.↵
    1. Colak Y,
    2. Nordestgaard BG,
    3. Afzal S.
    Morbidity and mortality in carriers of the cystic fibrosis mutation CFTR Phe508del in the general population. Eur Respir J 2020; 56.
  46. 46.↵
    1. Al-Sadeq D,
    2. Abunada T,
    3. Dalloul R,
    4. Fahad S,
    5. Taleb S,
    6. Aljassim K, et al.
    Spectrum of mutations of cystic fibrosis in the 22 Arab countries: A systematic review. Respirology. 2019; 24: 127–136.
    OpenUrl
  47. 47.↵
    1. Banjar H,
    2. Chaballout M,
    3. Karkour K,
    4. Al-Ghamdi H,
    5. Al-Mogarri I,
    6. Al-Haider S, et al.
    The prevalence of viral infections in children with cystic fibrosis in a tertiary care center in Saudi Arabia. Int J Pediatr Adolesc Med 2020; 7: 83–87.
    OpenUrl
  48. 48.↵
    1. Silva Filho LV,
    2. Castanos C,
    3. Ruiz HH.
    Cystic fibrosis in Latin America-Improving the awareness. J Cyst Fibros 2016; 15: 791–793.
    OpenUrl
  49. 49.↵
    1. Gibson RL,
    2. Burns JL,
    3. Ramsey BW.
    Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168: 918–951.
    OpenUrlCrossRefPubMedWeb of Science
  50. 50.↵
    1. Burns JL,
    2. Rolain J-M.
    Culture-based diagnostic microbiology in cystic fibrosis: Can we simplify the complexity? J Cyst Fibros 2014; 13: 1–9.
    OpenUrlCrossRefPubMed
  51. 51.↵
    1. Steinkamp G,
    2. Wiedemann B,
    3. Rietschel E,
    4. Krahl A,
    5. Gielen J,
    6. Bärmeier H, et al.
    Prospective evaluation of emerging bacteria in cystic fibrosis. J Cyst Fibros 2005; 4: 41–48.
    OpenUrlCrossRefPubMed
  52. 52.↵
    1. Camus L,
    2. Briaud P,
    3. Vandenesch F,
    4. Moreau K.
    How bacterial adaptation to cystic fibrosis environment shapes interactions between Pseudomonas aeruginosa and Staphylococcus aureus. Front Microbiol 2021; 12: 617784.
    OpenUrl
  53. 53.↵
    1. Burns JL,
    2. Gibson RL,
    3. McNamara S,
    4. Yim D,
    5. Emerson J,
    6. Rosenfeld M, et al.
    Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001; 183: 444–452.
    OpenUrlCrossRefPubMedWeb of Science
  54. 54.↵
    1. Hauser AR,
    2. Jain M,
    3. Bar-Meir M,
    4. McColley SA.
    Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev 2011; 24: 29–70.
    OpenUrlAbstract/FREE Full Text
  55. 55.↵
    1. Godoy JM,
    2. Godoy AN,
    3. Ribalta G,
    4. Largo I.
    Bacterial pattern in chronic sinusitis and cystic fibrosis. Otolaryngol Head Neck Surg 2011; 145: 673–676.
    OpenUrlCrossRefPubMedWeb of Science
  56. 56.↵
    1. Banjar H,
    2. Rt L,
    3. Alsheikh H,
    4. Abuzubida A,
    5. Almelhem J,
    6. Wagley Z, et al.
    Correlation of Cystic Fibrosis Mutations (CFTR) and Bacteria in a Tertiary Care Center in Saudi Arabia. Journal of MAR Pediatrics 2021; 1:1–11.
    OpenUrl
  57. 57.↵
    1. Waters V,
    2. Atenafu EG,
    3. Lu A,
    4. Yau Y,
    5. Tullis E,
    6. Ratjen F.
    Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. J Cyst Fibros 2013; 12: 482–486.
    OpenUrlCrossRefPubMed
  58. 58.
    1. Goss CH,
    2. Otto K,
    3. Aitken ML,
    4. Rubenfeld GD.
    Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am J Respir Crit Care Med 2002; 166: 356–361.
    OpenUrlCrossRefPubMedWeb of Science
  59. 59.↵
    1. Granchelli AM,
    2. Adler FR,
    3. Keogh RH,
    4. Kartsonaki C,
    5. Cox DR,
    6. Liou TG.
    Microbial interactions in the cystic fibrosis airway. J Clin Microbiol 2018; 56.
  60. 60.↵
    1. Phang SH,
    2. Greysson-Wong J,
    3. Somayaji R,
    4. Storey DG,
    5. Rabin HR,
    6. Surette MG, et al.
    Incidence, impact and natural history of Klebsiella species infections in cystic fibrosis: A longitudinal single center study. Can J Respir Crit 2019; 3: 148–154.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords